Saltar al contenido
Merck
Todas las fotos(1)

Documentos

I-011

Supelco

Iloperidone solution

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):
C24H27FN2O4
Número de CAS:
133454-47-4
Peso molecular:
426.48
Número MDL:
MFCD00866688
Código UNSPSC:
41116107
ID de la sustancia en PubChem:
329815298
NACRES:
NA.24

grado

certified reference material

formulario

liquid

Características

Snap-N-Spike®/Snap-N-Shoot®

envase

ampule of 1 mL

fabricante / nombre comercial

Cerilliant®

concentración

1.0 mg/mL in methanol

técnicas

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

aplicaciones

pharmaceutical (small molecule)

formato

single component solution

temp. de almacenamiento

−20°C

cadena SMILES

CC(C1=CC=C(OCCCN2CCC(C3=NOC4=C3C=CC(F)=C4)CC2)C(OC)=C1)=O

InChI

1S/C24H27FN2O4/c1-16(28)18-4-7-21(23(14-18)29-2)30-13-3-10-27-11-8-17(9-12-27)24-20-6-5-19(25)15-22(20)31-26-24/h4-7,14-15,17H,3,8-13H2,1-2H3

Clave InChI

XMXHEBAFVSFQEX-UHFFFAOYSA-N

Información sobre el gen

human ... DRD2(1813) , HTR2A(3356)

Descripción general

Iloperidone is an atypical antipsychotic administered for the treatment of schizophrenia. The drug is marketed under the trade names Fanapt and Fanapta. This Certified Spiking Solution® is suitable for use in LC/MS or GC/MS applications including clinical toxicology, forensic testing, or pharmaceutical research.

Información legal

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

Palabra de señalización

Danger

Clasificaciones de peligro

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

Órganos de actuación

Eyes

Código de clase de almacenamiento

3 - Flammable liquids

Clase de riesgo para el agua (WGK)

WGK 1

Punto de inflamabilidad (°F)

49.5 °F - closed cup

Punto de inflamabilidad (°C)

9.7 °C - closed cup

Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Peter J Weiden
Clinical schizophrenia & related psychoses, 6(1), 34-44 (2012-03-29)
Iloperidone is a second-generation "atypical" antipsychotic whose primary mechanism of action is within the subclass of combined D2/5HT2A antagonism. Iloperidone was approved by the FDA in May 2009 for the treatment of schizophrenia. This review is a comprehensive synthesis of
Radha Charan Dash et al.
Molecular diversity, 16(2), 367-375 (2011-12-14)
The dopamine D(2) receptor is involved in the etiology of a number of disorders, such as Parkinson's disease, Huntington's Chorea, tardive dyskinesia and schizophrenia. Antagonism of D(2) receptors is implicated in the treatment of various psychiatric disorders. In order to
Heidi N Boyda et al.
PloS one, 8(1), e53459-e53459 (2013-01-18)
The second generation antipsychotic (SGA) drugs are widely used in psychiatry due to their clinical efficacy and low incidence of neurological side-effects. However, many drugs in this class cause deleterious metabolic side-effects. Animal models accurately predict metabolic side-effects for SGAs
Bonnie A Fijal et al.
The Journal of clinical psychiatry, 73(3), 367-371 (2011-08-05)
We examined 6 single nucleotide polymorphisms (SNPs) previously reported to be associated with response to iloperidone therapy for association with response to risperidone therapy. Patients with schizophrenia (DSM-IV) were assessed during 2006 and 2007 for response/nonresponse (defined as ≥ 20%/<20%
Frank I Tarazi et al.
Expert opinion on pharmacotherapy, 13(13), 1911-1922 (2012-08-02)
Three newer atypical antipsychotic drugs were FDA-approved in 2009 and 2010 in the following order: iloperidone, asenapine and lurasidone. The three drugs are indicated for the treatment of acute schizophrenia. Asenapine is also approved for treatment of manic or mixed
Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico